A news article previewing early clinical research on an experimental oral Alzheimer’s treatment and what the study’s biomarker-focused analysis explores.
Key Takeaways
- LM11A-31, an oral p75NTR modulator, was analyzed using metabolic brain functional-network connectivity mapping
- Analysis used data from a Phase 2a randomized study enrolling 242 participants and multiple biomarkers
- Drug-treated participants showed a reported 50% reduction in cognitive progression on ADAS‑cog13 and MMSE versus placebo